Part I Item 1A. Risk Factors in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following: We are a commercial-stage biopharmaceutical company with four products approved for commercial sale. We have incurred significant losses since our inception, and could continue to incur losses, which, together with our limited history as a commercial-stag...
Q2 FY2026 — expected 2026-08-09
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ARQT | discussed_in_filing Artificial Intelligence | |
| topic_mention | ARQT | discussed_in_filing Cybersecurity | |
| topic_mention | ARQT | discussed_in_filing Trusted Computing | |
| topic_mention | ARQT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ARQT | discussed_in_filing Regulation | |
| topic_mention | ARQT | discussed_in_filing Healthcare & Bio | |
| topic_mention | ARQT | discussed_in_filing Platform & Ecosystem | |
| topic_mention | ARQT | discussed_in_filing Sovereign & Government | |
| topic_mention | ARQT | discussed_in_filing Artificial Intelligence | |
| topic_mention | ARQT | discussed_in_filing Cybersecurity | |
| topic_mention | ARQT | discussed_in_filing Trusted Computing | |
| topic_mention | ARQT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | ARQT | discussed_in_filing Regulation | |
| topic_mention | ARQT | discussed_in_filing Healthcare & Bio | |
| topic_mention | ARQT | discussed_in_filing Platform & Ecosystem | |
| topic_mention | ARQT | discussed_in_filing Sovereign & Government | |
| topic_mention | ARQT | discussed_in_filing Artificial Intelligence | |
| topic_mention | ARQT | discussed_in_filing Cybersecurity | |
| topic_mention | ARQT | discussed_in_filing Trusted Computing | |
| topic_mention | ARQT | discussed_in_filing Blockchain & Crypto |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001787306-26-000018 | EDGAR | 101K words |
| 2025-02-25 | 2024-12-31 | 0001787306-25-000029 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001787306-24-000031 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001787306-23-000023 | EDGAR | — |
| 2022-02-22 | 2021-12-31 | 0001787306-22-000009 | EDGAR | — |
| 2021-02-16 | 2020-12-31 | 0001628280-21-002272 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001787306-20-000005 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-28 | 2025-09-30 | 0001787306-25-000144 | EDGAR | 23K words |
| 2025-08-06 | 2025-06-30 | 0001787306-25-000124 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001787306-25-000092 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001787306-24-000153 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001787306-24-000124 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001787306-24-000079 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0001787306-23-000124 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001787306-23-000077 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001787306-23-000044 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001787306-22-000071 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001787306-22-000051 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001787306-22-000032 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-25 | 0001787306-26-000017 | EDGAR | 3K words |
| 2025-12-08 | 0001787306-25-000147 | EDGAR | — |
| 2025-10-28 | 0001787306-25-000142 | EDGAR | — |
| 2025-08-06 | 0001787306-25-000122 | EDGAR | — |
| 2025-06-17 | 0001787306-25-000096 | EDGAR | — |
| 2025-05-06 | 0001787306-25-000091 | EDGAR | — |
| 2025-04-10 | 0001787306-25-000058 | EDGAR | — |
| 2025-02-25 | 0001787306-25-000028 | EDGAR | — |
| 2025-01-13 | 0001787306-25-000004 | EDGAR | — |
| 2024-11-06 | 0001787306-24-000151 | EDGAR | — |
118 total filings indexed. 89 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001787306 |
| Ticker | ARQT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report